NCT04128696 · Interventional trial
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Overall registry status Terminated
Phase 3
Conditions Neoplasms, Head and Neck
Delaware Valley sites
- GSK Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory